MMP Inhibitor Clinical Trials – The Past, Present, and Future
Various pharmacological inhibitors of matrix metalloproteinases (MMPs) have been tested in phase I, II, and III trials of multiple cancer types and no significant evidence of efficacy has emerged. This overwhelming failure has understandably led to questions regarding MMPs as suitable drug targets in the oncology setting. In this chapter, a synopsis of the various trials and their results is presented along with a discussion of dose-limiting toxicities and the contrasting successful preclinical testing of these agents. Thoughtful application of the lessons learnt from the MMP inhibitor clinical experience should improve the likelihood of successful proteinase inhibitors in the future.
KeywordsClin Oncol Advanced Pancreatic Cancer Malignant Pleural Effusion Matrix Metalloproteinase Inhibitor Sideroblastic Anemia
Unable to display preview. Download preview PDF.